The Expression Pattern of ZIC5 and Its Prognostic Value in Lung Cancer

Lung Cancer
07/07/2020

Dong C, et al. Cancer Biother Radiopharm 2020.

ABSTRACT

Backgrounds: Lung cancer (LC) represents a leading cause of cancer-related deaths. The aim of this study was to analyze the application value of ZIC5 in the prognosis evaluation of LC. Materials and Methods: The mRNA and protein levels of ZIC5 in LC tissues and adjacent normal controls were detected by quantitative real-time polymerase chain reaction and Western blot analysis, respectively. Chi-square test was performed to estimate the association between ZIC5 expression and clinical features. Furthermore, overall survival (OS) curves were plotted using Kaplan-Meier method with log rank test. The prognosis analysis was analyzed using Cox proportional hazards model. Results: Compared with that of noncancerous tissues, the expression of ZIC5 in LC tissues was significantly increased at both protein and mRNA levels (p < 0.001). Moreover, ZIC5 expression showed a positive correlation with differentiation (p = 0.001) and tumor size (p = 0.016). Survival analysis suggested that high expression of ZIC5 predicted shorter OS (log rank test, p = 0.007). ZIC5 might be an independent prognostic biomarker for LC (hazard ratio = 2.892; 95% confidence interval, 1.297-6.449; p = 0.009). Conclusions: ZIC5 expression is upregulated in LC, and it may be employed as a prognostic biomarker for patients with LC.